Oncodesign Announces Publication of an Abstract for the 54th ASCO Annual Meeting in Chicago
May 18 2018 - 2:02PM
Business Wire
Publication of phase 1 interim results on the
first radiotracer generated by Oncodesign’s Nanocyclix®
technology
Regulatory News:
ONCODESIGN (Paris:ALONC) (ALONC – FR0011766229), a
biopharmaceutical company specializing in precision medicine,
announces the publication of an abstract presenting the interim
results of the first 12 patients participating in its clinical
study with its first radiotracer, for the 54th annual
meeting of ASCO (American Society of Clinical Oncology) in Chicago,
USA.
The primary objective of this clinical study is to assess the
clinical interest of the 18F-ODS2004436 radiotracer in PET1
imaging, by determining its sensitivity and specificity in patients
with non-small cell lung cancer.
In the first stage of the clinical study, 8 patients with EGFR
mutations received an injection of the radiotracer. Results showed
that the radiotracer did reach and bind to its target, whether a
primary or metastatic tumor. The signal reduction after one week’s
treatment confirmed the presence of the therapeutic molecule within
the tumor. In two of these patients, the radiotracer also alerted
the oncologist to the presence of brain metastases, which had gone
unnoticed until then.
The results presented at ASCO also include the first four
patients recruited in the study’s second stage. These initial
results in patients with no EGFR mutation validate the specificity
of the radiotracer.
“This 18F-fluorine-labeled radiotracer is a molecule generated
using Oncodesign’s Nanocyclix® technology. These interim results
reported for ASCO are promising and confirm the preclinical
results,” said Philippe Genne, founder, Chairman and CEO of
Oncodesign. “The opportunity to present these results at the
ASCO annual meeting, the leading event for the international
oncology community, is extremely important for Oncodesign and for
the visibility of this highly innovative program able to guide
clinicians on treatment selection.”
Every year, 30,000 oncology experts attend the ASCO meeting to
review the latest advances in cancer research. Researchers,
physicians and caregivers come to share the results of their
clinical and translational work.
The abstract is available on line on ASCO’s website:
https://meetinglibrary.asco.org/record/164926/abstract
About ONCODESIGN: www.oncodesign.com
Founded over 20 years ago by Dr Philippe Genne, the Company’s
CEO and Chairman, Oncodesign is a biopharma company dedicated to
the precision medicine. With its unique experience acquired by
working with more than 600 clients, including the world’s largest
pharmaceutical companies, along with its comprehensive
technological platform combining state-of-the-art medicinal
chemistry, pharmacology, regulated bioanalysis and medical imaging,
Oncodesign is able to predict and identify, at a very early stage,
each molecule's therapeutic usefulness and potential to become an
effective drug. Applied to kinase inhibitors, which represent a
market estimated at over $46 billion in 2016 and accounting for
almost 25% of the pharmaceutical industry’s R&D expenditure,
Oncodesign’s technology has already enabled the targeting of
several promising molecules with substantial therapeutic potential,
in oncology and elsewhere, along with partnerships with
pharmaceutical groups such as Bristol-Myers Squibb and UCB.
Oncodesign is based in Dijon, France, in the heart of the town’s
university and hospital hub, and within the Paris-Saclay cluster,
Oncodesign has 220 employees and subsidiaries in Canada and
the USA.
1 Positron Emission Tomography, a standard technique in clinical
diagnostics
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180518005623/en/
OncodesignPhilippe Genne, +33 (0)3 80 78 82 60Chairman
and CEOinvestisseurs@oncodesign.comorNewCapInvestor &
Media RelationsJulien Perez / Arthur Rouillé, +33 (0)1 44 71 98
52oncodesign@newcap.eu